On November 12, 2021 Actym Therapeutics reported that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors (Press release, Actym Therapeutics, NOV 12, 2021, View Source [SID1234595484]). ACTM-838 is based on the company’s immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells . ACTM-838 is a STACT strain that encodes engineered IL-15 (IL-15plex) and STING (eSTING). In preclinical studies, the IL-15plex + eSTING payload combination delivered by STACT resulted in primary human and mouse M2 macrophage production of type I interferon, and repolarization into a novel hybrid M1/M2 phenotype capable of tumor cell phagocytosis and priming of CD8+ T-cells. Complete tumor responses were observed in metastatic, checkpoint refractory tumors (IV dosing), that were entirely dependent on CD8+ T-cells. In primates, the therapy was well tolerated, rapidly cleared, and elicited minimal cytokine responses after IV dosing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The nomination of a lead candidate is a tremendous accomplishment for our company, and we’re excited about the possibility of bringing a desperately needed treatment option to cancer patients," said Christopher Thanos, Ph.D., Cofounder and Chief Executive Officer of Actym Therapeutics.
Actym’s data will be presented on Friday, November 12, 2021, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in Washington D.C. (Presentation #853, Novel Single Agent Immunotherapies).